Biweekly or Monthly Injections: For ongoing maintenance or prevention of deficiency
Consequently, in the CY 2026 PFS proposed rule we proposed to amend our requirements at 425.110(a)(2) to specify that, for agreement periods beginning on or after January 1, 2027, ACOs applying to enter a new agreement period would be required to have at least 5,000 assigned beneficiaries in the ACO's BY3 but could be under 5,000 assigned beneficiaries in BY1, BY2, or both
Response: We appreciate the commenters for their suggestion on an alternative ASM redistribution percentage
However, the strongest option is not always the best option for every individual
Reported or plausible effects may include headache, nausea, dizziness, flushing, fatigue, or changes in sleep